CYMABAY THERAPEUTICS Reports Third Quarter FY2023 Earnings Results
November 21, 2023
🌥️Earnings Overview
CYMABAY THERAPEUTICS ($NASDAQ:CBAY) released their earnings results for the third quarter of FY2023 on September 30, 2023. Total revenue for the quarter amounted to USD 0.0 million, a decrease from the USD 0.0 million during the same quarter of the prior year. The company reported a net income of USD -33.9 million, in comparison to -24.5 million a year earlier.
Price History
The stock opened at $16.4 and closed at the same level, its closing price being unchanged on the day. The company’s stock remained unchanged on the day, hinting at investor optimism for further growth in the near future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Cymabay Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 31.02 | -90.1 | -290.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Cymabay Therapeutics. More…
| Operations | Investing | Financing |
| -63.91 | -36.11 | 343.04 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Cymabay Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 451.05 | 124.86 | 2.9 |
Key Ratios Snapshot
Some of the financial key ratios for Cymabay Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -232.7% |
| FCF Margin | ROE | ROA |
| -206.9% | -20.8% | -10.0% |
Analysis
At GoodWhale, we have conducted a thorough analysis of CYMABAY THERAPEUTICS‘s fundamentals. Based on our Star Chart, the company has an intermediate health score of 4/10 with regard to its cashflows and debt, indicating that it is likely to safely ride out any crisis without the risk of bankruptcy. We have classified CYMABAY THERAPEUTICS as a ‘cheetah’, a type of company that has achieved high revenue or earnings growth but is considered less stable due to lower profitability. Investors who are looking for high returns in a shorter period of time and are willing to take on higher risk may find CYMABAY THERAPEUTICS attractive. Despite its weak profitability, the company is strong in asset and growth, making it a potential target for investors who have a higher tolerance for risk. More…
Peers
The competition in the pharmaceutical industry is fierce. Companies are constantly vying for market share and mind share. CymaBay Therapeutics Inc is no exception. The company competes with Acumen Pharmaceuticals Inc, Rocket Pharmaceuticals Inc, and Corvus Pharmaceuticals Inc. All of these companies are striving to develop the best products and therapies to help patients.
– Acumen Pharmaceuticals Inc ($NASDAQ:ABOS)
Acumen Pharmaceuticals Inc is a pharmaceutical company with a market cap of 322.81M as of 2022. The company has a Return on Equity of -9.46%. Acumen Pharmaceuticals Inc is a specialty pharmaceutical company that focuses on the development and commercialization of prescription drugs for the treatment of serious and life-threatening diseases. The company’s product pipeline includes products for the treatment of cancer, infectious diseases, and cardiovascular and central nervous system disorders.
– Rocket Pharmaceuticals Inc ($NASDAQ:RCKT)
Roche Pharmaceuticals Inc is a global healthcare company that focuses on the research, development, manufacture and commercialization of innovative pharmaceutical and diagnostic products. Its products and services address the prevention, diagnosis and treatment of diseases in six therapeutic areas: immunology, oncology, infectious diseases, ophthalmology, neuroscience and transplantation. The company has a market cap of 1.32B as of 2022 and a ROE of -46.52%. Roche’s products and services are sold in over 150 countries through a network of more than 2,000 distributors and wholesalers.
– Corvus Pharmaceuticals Inc ($NASDAQ:CRVS)
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapies. The company’s lead product candidate, CPI-444, is a small molecule antagonist of the adenosine A2A receptor being evaluated in a Phase 1/2 clinical trial in patients with various solid tumors, as well as in combination with other immuno-oncology agents.
Summary
CYMABAY THERAPEUTICS reported their financial results for Q3 FY2023, with total revenue for the quarter at USD 0.0 million, a decrease of 0.0 million compared to the same quarter in the prior year. Net income for the quarter was USD -33.9 million, which was also a decrease from -24.5 million in the previous year. This indicates that overall, CYMABAY THERAPEUTICS’ financial performance is not as strong as it was before, and investors should take this into account when making their decisions to invest in the company.
Related Posts
Recent Posts
